PharmaForceIQ Unveils New AI Capability to Enhance Biopharma Visibility and Response Accuracy

PharmaForceIQ Enhances AI Visibility with Share of Answer Module

PharmaForceIQ has launched its latest feature, the Share of Answer (SoA) module, designed to integrate AI visibility audits with actionable insights, significantly transforming how biopharma companies manage their visibility in AI-generated health information. This new capability is part of their Optichannel 360 platform, aimed at ensuring that the digital representation of treatments and disease education is both accurate and effective.

In today's digital age, the demand for reliable medical information is surging, particularly as healthcare professionals (HCPs) and patients increasingly turn to AI tools for answers. With the rise in AI-generated content, concerns about the accuracy of information supplied have become critical. PharmaForceIQ's SoA module addresses this issue by auditing how therapies are represented in AI responses to clinical questions, enabling companies to gauge their performance and act accordingly.

Recent analyses by PharmaForceIQ revealed some concerning statistics regarding AI visibility. On average, brand and condition websites constituted only 17% of citations in responses generated by AI, highlighting a significant gap in reliable information. Furthermore, audits identified numerous instances where outdated or invalid data was cited in responses, including references to retired webpages and superseded FDA-approved labels. The challenges are evident: how to ensure that AI-generated medical responses reflect the most current, reliable clinical evidence available.

The Share of Answer metric quantifies how often a brand or therapy is accurately represented in relevant AI-generated answers, demonstrating its visibility. This measurement goes beyond mere mention; it assesses four critical dimensions of each AI response:
1. Present: Is the brand or therapy mentioned in relevant queries?
2. Accurate: Does the response align with current approved evidence without outdated or unsupported claims?
3. Preferred: Is there a clear differentiation of the therapy compared to alternatives?
4. Cited: Are authoritative sources, such as peer-reviewed studies, referenced?

Hemal Somaiya, Chief Executive and Strategy Officer at PharmaForceIQ, emphasized the importance of accuracy, stating that when clinicians inquire about a therapy, the information they receive must reflect the established evidence. The Share of Answer module provides biopharma teams with essential insights into how their treatments are perceived by AI tools and highlights areas needing improvement.

Data from visibility audits further elaborated on existing gaps in AI-generated information. With only 17% of approved content cited and many outdated sources still visible, the need for proactive measures is clear. For instance, some analyses found that AI responses wrongly identified rare diseases, showcasing the challenges of incorrect terminology usage. When full names of conditions were used, AI responses improved, but the identification rate plummeted when abbreviations appeared.

The power of the SoA module lies in its diagnostic approach, converting findings into prioritized actions. This ensures that each claim is associated with a verifiable source, improving digital visibility and credibility. In controlled trials, this actionable framework dramatically improved answer accuracy—for one AI engine, accuracy soared from 40% to an impressive 95%.

PharmaForceIQ's innovations in precision customer engagement empower pharmaceutical leaders to accurately target and engage HCP and patient audiences throughout the product lifecycle. By aiding biopharma teams in optimizing their AI content strategy, PharmaForceIQ is not just addressing the challenges of today but is also laying the groundwork for a more informed healthcare future. To discover more about this pioneering solution and the complete Optichannel 360 suite, visit pharmaforceiq.com.